» Authors » Rajkumar Lalji Sahani

Rajkumar Lalji Sahani

Explore the profile of Rajkumar Lalji Sahani including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 161
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Guthrie D, Saathoff J, Sahani R, Nunes De Souza A, Cook D, Hochstetler S, et al.
Org Process Res Dev . 2024 Aug; 28(8):3197-3205. PMID: 39171130
Herein, we describe two practical approaches to synthesize ()-(+)-1,2-epoxy-5-hexene from inexpensive and readily available raw materials and reagents. The first approach is a two-step sequence, involving an epoxidation with -chloroperoxybenzoic...
2.
Mangunuru H, Terrab L, Janganati V, Kalikinidi N, Tenneti S, Natarajan V, et al.
J Org Chem . 2024 Apr; 89(9):6085-6099. PMID: 38648720
Herein, we disclose a facile synthetic strategy to access an important class of drug molecules that contain chiral 1,2-amino alcohol functionality utilizing highly effective ruthenium-catalyzed asymmetric transfer hydrogenation of unprotected...
3.
Senaweera S, Edwards T, Kankanala J, Wang Y, Sahani R, Xie J, et al.
Acta Pharm Sin B . 2022 Jul; 12(4):1671-1684. PMID: 35847513
Current drugs for treating human cytomegalovirus (HCMV) infections are limited by resistance and treatment-associated toxicities. In developing mechanistically novel HCMV antivirals, we discovered an -benzyl hydroxypyridone carboxamide antiviral hit ()...
4.
Sahani R, Akther T, Cilento M, Castaner A, Zhang H, Kirby K, et al.
RSC Med Chem . 2022 Jan; 12(12):2031-2044. PMID: 35028563
PF74 (1) is a potent and well-characterized prototypical small molecule targeting human immunodeficiency virus type 1 (HIV-1) capsid protein (CA), but not a viable antiviral lead due to the lack...
5.
Wang L, Edwards T, Sahani R, Xie J, Aihara H, Geraghty R, et al.
Eur J Med Chem . 2021 Jun; 222:113640. PMID: 34147908
The genome packaging of human cytomegalovirus (HCMV) requires a divalent metal-dependent endonuclease activity localized to the C-terminus of pUL89 (pUL89-C), which is reminiscent of RNase H-like enzymes in active site...
6.
Sahani R, Diana-Rivero R, Vernekar S, Wang L, Du H, Zhang H, et al.
Viruses . 2021 Apr; 13(3). PMID: 33804121
Small molecules targeting the PF74 binding site of the HIV-1 capsid protein (CA) confer potent and mechanistically unique antiviral activities. Structural modifications of PF74 could further the understanding of ligand...
7.
Wang L, Casey M, Vernekar S, Sahani R, Kirby K, Du H, et al.
Acta Pharm Sin B . 2021 Mar; 11(3):810-822. PMID: 33777683
Of all known small molecules targeting human immunodeficiency virus (HIV) capsid protein (CA), PF74 represents by far the best characterized chemotype, due to its ability to confer antiviral phenotypes in...
8.
Wang L, Casey M, Vernekar S, Sahani R, Kankanala J, Kirby K, et al.
Eur J Med Chem . 2020 Aug; 204:112626. PMID: 32814250
The PF74 binding site in HIV-1 capsid protein (CA) is a compelling antiviral drug target. Although PF74 confers mechanistically distinct antiviral phenotypes by competing against host factors for CA binding,...
9.
Ye L, Zhu X, Sahani R, Xu Y, Qian P, Liu R
Chem Rev . 2020 Aug; 121(14):9039-9112. PMID: 32786423
Catalytic transformations involving metal carbenes are considered one of the most important aspects of homogeneous transition metal catalysis. Recently, gold-catalyzed generation of gold carbenes from readily available alkynes represents a...
10.
Wang L, Casey M, Vernekar S, Do H, Sahani R, Kirby K, et al.
Eur J Med Chem . 2020 May; 200:112427. PMID: 32438252
The capsid protein (CA) of HIV-1 plays essential roles in multiple steps of the viral replication cycle by assembling into functional capsid core, controlling the kinetics of uncoating and nuclear...